Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29263596 | 0.96 | ALDH1A1 (0.35) | CYP1A2CYP3A4ALDH1A1MAPTCYP2C9 | |
| SCHEMBL22618750 | 0.88 | FAAH (0.36) | CYP1A2CYP3A4ALDH1A1MAPTCYP2C9 | |
| SCHEMBL30674488 | 0.87 | ALDH1A1 (0.32) | CYP1A2CYP3A4ALDH1A1MAPTCYP2C9 | |
| SCHEMBL22561348 | 0.87 | ALDH1A1 (0.32) | CYP1A2CYP3A4ALDH1A1MAPTCYP2C9 | |
| SCHEMBL21137867 | 0.85 | CYP1A2 (0.34) | CYP1A2CYP3A4ALDH1A1MAPTCYP2C9 | |
| SCHEMBL25045553 | 0.81 | FFAR1 (0.32) | ALDH1A1MAPT | |
| SCHEMBL22618814 | 0.81 | FFAR1 (0.32) | ALDH1A1MAPTITGB1ITGA4 | |
| SCHEMBL22551277 | 0.81 | FFAR1 (0.40) | ALDH1A1MAPTITGB1ITGA4 | |
| SCHEMBL22618760 | 0.80 | ITGB1 (0.41) | CYP1A2CYP3A4ALDH1A1MAPTCYP2C9 | |
| SCHEMBL30107915 | 0.80 | ACACB (0.34) | CYP1A2CYP3A4ALDH1A1MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026086740-A1 | USE AND METHOD OF BISPECIFIC ANTIBODY-DRUG CONJUGATES FOR TREATING TUMOR DISEASES | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026086737-A1 | USES AND METHODS OF BISPECIFIC ANTIBODY-DRUG CONJUGATES FOR TREATING TUMOR DISEASES | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2026-04-30 | — | — | WO | disclosed |
| EP-3725798-B1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20260027224-A1 | ANTIBODY-DRUG CONJUGATES TARGETING CDH3 AND PREPARATION METHODS AND USES THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-29 | — | — | US | disclosed |
| EP-4673475-A1 | ANTIBODY-DRUG CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | MULTITUDE THERAPEUTICS INC. (CN) | 2026-01-07 | — | — | EP | disclosed |
| EP-4667495-A2 | BIOACTIVE MOLECULE CONJUGATE, PREPARATION METHOD AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-12-24 | — | — | EP | disclosed |
| US-20250281631-A1 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| EP-4603487-A1 | HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-20 | — | — | EP | disclosed |
| EP-4603109-A1 | ANTIBODY-DRUG CONJUGATE, PREPARATION METHOD THEREFOR, AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-20 | — | — | EP | disclosed |
| EP-4601701-A1 | ANTIBODY-DRUG CONJUGATE BINDING TO HUMAN PTK7 AND METHOD FOR PREPARATION AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2025-08-20 | — | — | EP | disclosed |
| CN-113683622-A | Bioactive substance conjugate and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-11-23 | — | — | CN | disclosed |
| CN-113651831-A | Bioactive substance conjugate and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-11-16 | — | — | CN | disclosed |
| CN-113603703-A | Bioactive substance conjugate and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-111295389-B | Bioactive substance conjugate and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2021-10-22 | — | — | CN | disclosed |
| US-20210101906-A2 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-04-08 | — | — | US | disclosed |
| US-20210101906-A2 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-04-08 | — | — | US | disclosed |
| US-20200347075-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-11-05 | — | — | US | disclosed |
| EP-3725798-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-10-21 | — | — | EP | disclosed |
| EP-3725798-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-10-21 | — | — | EP | disclosed |
| CN-111295389-A | Bioactive substance conjugate and preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2020-06-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027224-A1 | ANTIBODY-DRUG CONJUGATES TARGETING CDH3 AND PREPARATION METHODS AND USES THEREOF | H1-3, H1-4, H1-2 | CYP1A2 2744/4885CYP3A4 2530/4885ALDH1A1 478/4885 |
| US-20200347075-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | DOCK11, PAICS, RHOA | CYP1A2 3650/4885CYP3A4 3557/4885ALDH1A1 1175/4885 |
| US-20210101906-A2 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | DOCK11, PAICS, RHOA | CYP1A2 3650/4885CYP3A4 3557/4885ALDH1A1 1175/4885 |
| US-20250281631-A1 | ANTIBODY-DRUG CONJUGATES AND PREPARATION METHODS AND USE THEREOF | TOP1, TOP2A, TOP2B | CYP1A2 1890/4885CYP3A4 1205/4885ALDH1A1 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.